Correspondence 0001493152-24-014541 from Calidi Biotherapeutics, Inc. (CLDI)
Calidi Biotherapeutics, Inc.
Date: April 15, 2024 · CIK: 0001855485 · Accession: 0001493152-24-014541
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276741
Letter
Executive Drive, Suite 200,
San Diego, California 92121
April 15, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Attention: Tyler Howes
Re:
Calidi Biotherapeutics, Inc.
Registration Statement on Form S-1 (File No. 333-276741)
Request for Acceleration
Requested Date: April 15, 2024
Requested Time: 4:30 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), the undersigned hereby respectfully requests that the effective date of its Registration Statement on Form S-1, as amended, (File No. 333-276741) be accelerated so that the same will become effective at 4:30 p.m., Eastern Time, on April 15, 2024, or as soon thereafter as is practicable. In making this acceleration request, the undersigned acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact our counsel Daniel B. Eng of Lewis Brisbois Bisgaard & Smith LLP at (415) 262-8508.
Very
Truly Yours,
Calidi
Biotherapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
4475
Executive Drive, Suite 200,
San
Diego, California 92121
April
15, 2024
VIA
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Attention:
Tyler Howes
Re:
Calidi
Biotherapeutics, Inc.
Registration
Statement on Form S-1 (File No. 333-276741)
Request
for Acceleration
Requested
Date: April 15, 2024
Requested
Time: 4:30 p.m. Eastern Time
Ladies
and Gentlemen:
In
accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), the undersigned hereby respectfully requests
that the effective date of its Registration Statement on Form S-1, as amended, (File No. 333-276741) be accelerated so that the same
will become effective at 4:30 p.m., Eastern Time, on April 15, 2024, or as soon thereafter as is practicable. In making this acceleration
request, the undersigned acknowledges that it is aware of its responsibilities under the Act.
If
you have any questions regarding this request, please contact our counsel Daniel B. Eng of Lewis Brisbois Bisgaard & Smith LLP at
(415) 262-8508.
Very
Truly Yours,
Calidi
Biotherapeutics, Inc.
By:
/s/
Andrew Jackson
Name:
Andrew
Jackson
Title:
Chief
Financial Officer